9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search

Phase I Study of OSI-930 and Erlotinib in Cancer Tumors

Estimated reading time: < 1 min

Condition

Advanced Solid Tumors

Estimated Enrollment: 60

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: OSI-930-103

Study First Received: December 26, 2007

Last Updated: September 26, 2011

Estimated Primary Completion Date: April 2010

Primary Outcome Measures:

Determine the maximum tolerated dose (MTD), evaluate the pharmacokinetic profiles|Safety, evaluate pharmacodynamic relationships

Sponsors and Collaborators:

Astellas Pharma Inc|OSI Pharmaceuticals

Result Received: No Study Results Posted

Website Link: https://ClinicalTrials.gov/show/NCT00603356

Was this article helpful?
Views: 5